Are your bones at risk if you are fighting breast cancer?

Written by: Professor Gordana Prelevic
Edited by: Jay Staniland

Breast cancer is the most common cancer in women, with around 1 in 8 women being diagnosed with breast cancer during their lifetime, with the majority of women being diagnosed after menopause.

Hormonal therapy (called adjuvant therapy) is usually given after the operation and following chemotherapy and/or radiotherapy for those women who had oestrogen receptor (ER) positive tumours. Both chemotherapy and some types of hormonal therapy speed up osteoporosis and the loss of bone density. Here leading consultant endocrinologist, Professor Gordana Prelevic, takes a look at the different medications used in the treatment of breast cancer, and the effects they have on bone health.




Tamoxifen has a beneficial effect on bone density in postmenopausal women, though its clinical use is limited to five years.


Aromatase inhibitors


Aromatase inhibitors (anastrozole, letrozole, exemestane) reduce the amount of oestrogen circulating in the body which may lead to osteoporosis. The risk of developing osteoporosis depends on how healthy the bones were before the breast cancer treatment.

Women who had good bone density before breast cancer treatment are less likely to develop osteoporosis while on aromatase inhibitor (AI) treatment than those who already had low bone density.

Women who are at a particularly high risk of experiencing negative effects of AI on their bone health are recently menopausal women (within four years of menopause), those who previously had chemotherapy, and those who previously had low bone density (BMD).

Other factors which increase the risk of developing osteoporosis while on AI are:

  • previous fracture
  • family history of hip fracture
  • being thin
  • smoking
  • having three or more alcoholic drinks per day
  • steroid treatment
  • certain diseases such as rheumatoid arthritis

Bone loss in women on AI appears to be continuous (while the woman is on therapy) with an increased risk of low trauma fracture by about 50%. However, recent data suggest that after the treatment ceases, this bone loss is reversible.

Standard treatments for osteoporosis like bisphosphonates (alendronic acid, risedronate, pamidronate and zoledronic acid) and denosumab are highly effective in preventing bone loss induced by AI.


What is your advice for women diagnosed with breast cancer?


Any woman with breast cancer who has had low trauma fracture or is postmenopausal or on AI therapy should have a DXA scan to assess her bone mass density.

If her T-score is below -2.0, treatment with bisphosphonate or denosumab should be initiated in addition to basic preventive measures.

The preventive measures include:

  • increasing your calcium intake to 1 - 1.5g daily (there is approximately 125mg in a glass of milk)
  • optimising vitamin D levels (usually achieved by taking 1000 - 2000IU of vitamin D daily)
  • weight-bearing and muscle-strengthening exercise

If you are concerned about the effects of breast cancer treatment on your bone health, make an appointment with an osteoporosis specialist.

By Professor Gordana Prelevic
Endocrinology, diabetes & metabolism

Professor Gordana Prelevic is one of London's leading endocrinologists. Her main area of expertise is reproductive endocrinology with special interests in the polycystic ovary syndrome, menopause and osteoporosis.

Professor Gordana Prelevic practises at the London Claremont Clinic and the Wellington Hospital (Platinum Medical Centre and Wellington Diagnostics and Outpatients Centre). She has published extensively in peer-reviewed journals and has contributed to numerous book chapters. She also works as an expert witness in endocrinology and forms an integral part of various reputable professional bodies.

View Profile

Overall assessment of their patients

We use cookies on this site to enhance your user experience. Click ‘Enter’ to continue browsing. Enter Cookies policy